Grifols (ADR) (GRFS)
Builds plasma-derived therapies, diagnostics, and biologic supplies around an integrated plasma network.
$7.29
vs last close−0.16 (−2.08%)
In millions of USD, except per-share figures · converted from EUR at the latest rate
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,820 | 2,016 | 1,852 | 2,071 | 2,043 | 2,251 | 2,035 | 2,155 | 2,126 | 2,237 | 1,969 | 2,135 |
| Cost of revenue | 1,100 | 1,230 | 1,114 | 1,308 | 1,215 | 1,378 | 1,232 | 1,307 | 1,269 | 1,462 | 1,251 | 1,333 |
| Gross profit | 720 | 786 | 739 | 764 | 828 | 873 | 803 | 848 | 856 | 775 | 718 | 802 |
| 434 | 496 | 507 | 423 | 467 | 450 | 497 | 450 | 420 | 465 | 430 | 427 | |
| Research & development | 100 | 136 | 103 | 103 | 100 | 131 | 109 | 110 | 111 | 154 | 104 | 98 |
| 329 | 555 | 360 | 341 | 364 | 180 | 359 | 322 | 312 | 311 | 325 | 329 | |
| General & administrative | 0 | 0 | 0 | 341 | 0 | 0 | 0 | 322 | 0 | 0 | 0 | 0 |
| Other expenses | 5 | −195 | 43 | −22 | 3 | 138 | 28 | 18 | −3 | 0 | 0 | 0 |
| Operating income | 286 | 290 | 232 | 341 | 361 | 424 | 306 | 398 | 437 | 310 | 288 | 375 |
| −172 | −170 | −179 | −265 | −225 | −184 | −175 | −180 | −211 | −185 | −159 | −93 | |
| Interest income | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 11 | 0 | 0 | 0 | 0 |
| Interest expense | 172 | 183 | 194 | 231 | 225 | 18 | 175 | 161 | 178 | 181 | 161 | 92 |
| Other non-operating income | 0 | 67 | −43 | 34 | −49 | 166 | −28 | 19 | 33 | 4 | −2 | −113 |
| Income before tax | 113 | 120 | 54 | 76 | 136 | 240 | 131 | 217 | 226 | 125 | 130 | 281 |
| Income tax expense | 6 | 32 | 28 | 48 | 43 | 144 | 26 | 59 | 62 | −17 | 28 | 73 |
| Net income from continuing operations | 107 | 89 | 25 | 28 | 93 | 95 | 105 | 158 | 163 | 142 | 102 | 209 |
| Net income | 68 | 64 | 24 | 17 | 59 | 79 | 68 | 133 | 145 | 111 | 85 | 175 |
| EPS, basic | $0.10 | $0.09 | $0.03 | $0.02 | $0.09 | $0.11 | $0.10 | $0.19 | $0.22 | $0.16 | $0.13 | $0.26 |
| EPS, diluted | $0.10 | $0.09 | $0.03 | $0.02 | $0.09 | $0.11 | $0.10 | $0.19 | $0.22 | $0.16 | $0.13 | $0.26 |
| Weighted average shares, basic | 679 | 679 | 711 | 742 | 680 | 680 | 680 | 689 | 681 | 681 | 681 | 681 |
| Weighted average shares, diluted | 679 | 679 | 711 | 742 | 680 | 680 | 680 | 689 | 681 | 681 | 681 | 681 |
| EBITDA | 409 | 344 | 396 | 339 | 533 | 383 | 461 | 396 | 521 | 451 | 411 | 610 |
| Depreciation & amortization | 123 | 120 | 120 | 32 | 123 | 125 | 127 | 17 | 117 | 145 | 120 | 122 |
| EBIT | 285 | 224 | 276 | 307 | 410 | 258 | 334 | 378 | 404 | 306 | 291 | 488 |